Bio-Rad Laboratories (NYSE: BIO) exec vests 246 RSUs, withholds shares
Rhea-AI Filing Summary
Eva Anette Engelhardt, EVP and President, CDG of Bio-Rad Laboratories, had 246 Restricted Stock Units vest and convert into 246 shares of Bio-Rad Class A common stock on July 25, 2026. To satisfy tax obligations, 89 of those shares were withheld at $314.4600 per share. After this vesting event, she continues to hold 492 Restricted Stock Units, which vest over four years at 25% per year on the grant anniversary.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 157 shares
Net Buy
3 txns
Insider
ENGELHARDT EVA ANETTE
Role
EVP, President, CDG
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F2, F3 | 246 | $0.00 | $0.00 |
| Exercise | Bio-Rad A Common Stock F1 | 246 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Bio-Rad A Common Stock | 89 | $314.46 | $28K |
Holdings After Transaction:
Restricted Stock Units — 492 shares (Direct);
Bio-Rad A Common Stock — 503 shares (Direct)
Footnotes (3)
- F1. Shares of Class A common stock acquired on the vesting of restricted stock units.
- F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
- F3. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Key Figures
RSUs Converted: 246.0000 units
Shares Acquired: 246.0000 shares
Shares Withheld for Taxes: 89.0000 shares
+3 more
6 metrics
RSUs Converted
246.0000 units
Restricted Stock Units vested and converted into Class A common shares on July 25, 2026
Shares Acquired
246.0000 shares
Bio-Rad Class A common stock received upon RSU vesting
Shares Withheld for Taxes
89.0000 shares
Shares withheld to satisfy tax obligations related to the vesting event
Tax Withholding Price
$314.4600 per share
Per-share value used for shares withheld to cover tax liability
RSUs Remaining
492.0000 units
Restricted Stock Units reported as held following the derivative transaction
RSU Vesting Rate
25% per year
Vesting schedule over four years on each grant anniversary
Key Terms
Restricted Stock Units, Exercise or conversion of derivative security, Payment of exercise price or tax liability
3 terms
Restricted Stock Units financial
"Security title reported as Restricted Stock Units in the derivative transaction."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Exercise or conversion of derivative security financial
"Transaction code M described as Exercise or conversion of derivative security."
Payment of exercise price or tax liability financial
"Code F described as Payment of exercise price or tax liability by delivering or withholding securities."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider equity transaction did Bio-Rad (BIO) report for Eva Anette Engelhardt?
Bio-Rad (BIO) reported that executive Eva Anette Engelhardt had 246 Restricted Stock Units vest and convert into 246 shares of Bio-Rad Class A common stock on July 25, 2026, as part of her equity compensation.
What is the vesting schedule of the Restricted Stock Units reported for Bio-Rad (BIO)?
The Restricted Stock Units vest over four years at 25% per year on the yearly anniversary of the grant date, meaning Engelhardt receives an additional quarter of the grant each year until fully vested.
How many Restricted Stock Units does the Bio-Rad (BIO) executive hold after this transaction?
After the July 25, 2026 transaction, Engelhardt holds 492 Restricted Stock Units. These remaining units continue to vest according to the four-year schedule, providing additional potential future shares of Bio-Rad Class A common stock.
Was the Bio-Rad (BIO) insider transaction made under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is unchecked, indicating the reported transactions were not affirmed as being executed under a pre-arranged 10b5-1 trading plan, but instead appear as regular equity compensation events.
What roles does the reporting person hold at Bio-Rad (BIO)?
The reporting person, Eva Anette Engelhardt, is identified as an officer of Bio-Rad Laboratories, serving as EVP, President, CDG, which reflects a senior executive leadership position at the company.